Last reviewed · How we verify
NG101
At a glance
| Generic name | NG101 |
|---|---|
| Also known as | metopimazine mesylate |
| Sponsor | Neurogastrx, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist (PHASE2)
- A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (PHASE2)
- NISCI - Nogo Inhibition in Spinal Cord Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NG101 CI brief — competitive landscape report
- NG101 updates RSS · CI watch RSS
- Neurogastrx, Inc. portfolio CI